CRNX - Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment Says Analyst | Benzinga
Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating and a price target of $40.
The analysts Leland Gershell and Rohan Mathur note significant room for improvement in drugs targeting various chronic endocrine disorders. Current options either have suboptimal benefit/risk profiles, problematic administration routes, or inadequate frequency.
The well-understood biology of peptide hormone signaling through G protein-coupled receptors makes them the therapeutic targets of choice, and Crinetics Pharmaceuticals is distinguished by its ability to create oral, once-daily non-peptide drug candidates to endocrine ...